



Catalog Number:	MC11091	Product Type:	Small Molecule
Bio-Activity:	Tankyrase inhibitor	CAS #:	284028-89-3
Research Categories:	Stem cells, cancer	Chemical Name:	2-[4-(Trifluoromethyl)phenyl]-7,8-dihydro-5H-thiino[4,3-d]pyrimidin-4-ol
Solubility:	Soluble in DMSO (up to 25 mg/ml).	Molecular Formula:	C ₁₄ H ₁₁ F ₃ N ₂ O ₂ S
Purity:	> 98%	Molecular Weight:	312.3
Format:	Powder	Ship Temp:	Ambient
Storage:	Room Temperature		

Application Notes

Description/Data:

Tankyrase inhibitor (IC₅₀=11 and 4 nM for TNKS1 and 2 respectively). Antagonizes Wnt signaling downstream of receptor activation via stabilization of axin, a negative regulator of β -catenin [1]. Robustly induces cardiomyogenesis of stem cells [2]. Reduces experimental fibrosis in a mouse model of bleomycin-induced dermal fibrosis [3]. Promotes apoptosis in a neuroblastoma cell line via telomere shortening [4]. An important tool for probing the activation of the Wnt/ β -catenin pathway in cells [5]. Cell permeable.

References:

- 1) S. Huang et al. Nature 2009 46:614
- 2) H Wang et al. ACS Chem. Biol. 2011 6:192
- 3) A Distler Wang et al. Ann. Rheum. Dis. 2013 72:1575
- 4) X Tian et al. Oncol. Rep. 2014 32:1999
- 5) KC Davidson et al. Proc. Natl. Acad. Sci. USA 2012 109:4485

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012